Interaction between oblongifolin C and UDP-glucuronosyltransferase isoforms in human liver and intestine microsomes

References

• Antoniou T, Gough K, Yoong D, Arbess G. (2004). Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis 38:e38–40
   Google Scholar
• Aprile S, Del Grosso E, Grosa G. (2010). Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4. Drug Metab Dispos 38:1141–6
   PubMed Web of Science ®Google Scholar
• Court MH, Krishnaswamy S, Hao Q, et al. (2003). Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125–33
   PubMed Web of Science ®Google Scholar
• Desai AA, Innocenti F, Ratain MJ. (2003). UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13:517–23
   PubMedGoogle Scholar
• Di Marco A, D'Antoni M, Attaccalite S, et al. (2005). Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 33:812–19
   PubMed Web of Science ®Google Scholar
• Feng C, Zhou LY, Yu T, et al. (2012). A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. Int J Cancer 131:1445–54
   PubMed Web of Science ®Google Scholar
• Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–97
   PubMed Web of Science ®Google Scholar
• Fujiwara R, Nakajima M, Yamanaka H, et al. (2008). Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab Dispos 36:361–7
   PubMed Web of Science ®Google Scholar
• Hamed W, Brajeul S, Mahuteau-Betzer F, et al. (2006). Oblongifolins A-D, polyprenylated benzoylphloroglucinol derivatives from Garcinia oblongifolia. J Nat Prod 69:774–7
   PubMed Web of Science ®Google Scholar
• Hirata-Koizumi M, Saito M, Miyake S, Hasegawa R. (2007). Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. J Clin Pharm Ther 32:177–85
   PubMed Web of Science ®Google Scholar
• Huang SX, Feng C, Zhou Y, et al. (2009). Bioassay-guided isolation of xanthones and polycyclic prenylated acylphloroglucinols from Garcinia oblongifolia. J Nat Prod 72:130–5
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700
   PubMed Web of Science ®Google Scholar
• Kostrubsky SE, Sinclair JF, Strom SC, et al. (2005). Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci 87:146–55
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Duan SX, Von Moltke LL, et al. (2003). Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 33:169–80
   PubMed Web of Science ®Google Scholar
• Lao Y, Wan G, Liu Z, et al. (2014). The natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation. Autophagy 10:736–49
   PubMed Web of Science ®Google Scholar
• Liu Y, Ramirez J, House L, Ratain MJ. (2010). Comparison of the drug–drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32–9
   PubMed Web of Science ®Google Scholar
• Mungmee C, Sitthigool S, Buakeaw A, Suttisri R. (2013). A new biphenyl and other constituents from the wood of Garcinia schomburgkiana. Nat Prod Res 27:1949–55
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya A, Czernik PJ, Little JM, et al. (1999). Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817–99
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121–32
   PubMed Web of Science ®Google Scholar
• Shi R, Yang YY, Zhong J, et al. (2014). Validated assay for the evaluation of multiple glucuronidation activities in human liver microsomes via liquid chromatography-tandem mass spectrometry. RSC Adv 4:56132–8
   Google Scholar
• Simpkins NS, Holtrup F, Rodeschini V, et al. (2012). Comparison of the cytotoxic effects of enantiopure PPAPs, including nemorosone and clusianone. Bioorg Med Chem Lett 22:6144–7
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, et al. (2004). Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 32:587–94
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1999). UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149–60
   PubMed Web of Science ®Google Scholar
• Tong Z, Li H, Goljer I, et al. (2007). In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 35:2203–10
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449–56
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Guo XH, et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413–23
   PubMed Web of Science ®Google Scholar
• Walsky RL, Bauman JN, Bourcier K, et al. (2012). Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 40:1051–65
   PubMed Web of Science ®Google Scholar
• Xu B, Gao S, Wu B, et al. (2014). Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities. J Pharm Biomed Anal 88:180–90
   PubMed Web of Science ®Google Scholar
• Xu G, Feng C, Zhou Y, et al. (2008). Bioassay and ultraperformance liquid chromatography/mass spectrometry guided isolation of apoptosis-inducing benzophenones and xanthone from the pericarp of Garcinia yunnanensis Hu. J Agric Food Chem 56:11144–50
   PubMed Web of Science ®Google Scholar
• Xu G, Kan WL, Zhou Y, et al. (2010). Cytotoxic acylphloroglucinol derivatives from the twigs of Garcinia cowa. J Nat Prod 73:104–8
   PubMed Web of Science ®Google Scholar